Abstract: A holder includes a vertical holding part configured to support an infant in a vertical posture so that the head is positioned vertically, in which the vertical holding part has a front pad part extending in a vertical direction and configured to support the infant from a front of the infant, at least from the abdomen to the chest of the infant.

Abstract: A holder includes a vertical holding part configured to support an infant in a vertical posture so that the head is positioned vertically, in which the vertical holding part has a front pad part extending in a vertical direction and configured to support the infant from a front of the infant, at least from the abdomen to the chest of the infant.

Abstract: A holder includes a vertical holding part configured to support an infant in a vertical posture so that the head is positioned vertically, in which the vertical holding part has a front pad part extending in a vertical direction and configured to support the infant from a front of the infant, at least from the abdomen to the chest of the infant.

Abstract: A holder includes a vertical holding part configured to support an infant in a vertical posture so that the head is positioned vertically, in which the vertical holding part has a front pad part extending in a vertical direction and configured to support the infant from a front of the infant, at least from the abdomen to the chest of the infant.

Abstract: The present invention provides a novel spiroistiquinoline derivative of the formula [I]: which has a small-conductance potassium channel (SK) blocking activity and is useful as a medicament, a method for preparing the same and an intermediate thereof.

Abstract: A data processor is provided to increase the number of instructions it can handle, even with a large number of operands required for the instructions. The data processor comprises a decoding circuit (1) extracting bits (a1, a2) of an instruction as first operand fields and decoding an operation code, using the remaining bits (a4); an operand-field storage portion (3) including a first operand-field storage portion (3a) storing bits (a1, a2) obtained from the decoding circuit (1) via a selector (2), and a second operand-field storage portion (3b) storing a second operand field obtained on the basis of those bits (a2); and a data processing portion (5) receiving the first and the second operand fields from the operand-field storage portion (3) and processing data in registers designated by the first and the second operand fields.

Abstract: Disclosed is a pyridazinone compound represented by the formula (I): ##STR1## wherein X represents hydrogen atom or the like; Y represents a single bonding arm, oxygen atom or sulfur atom; A represents a straight or branched alkylene group which may have a double bond;B represents carbonyl group or thiocarbonyl group; and R.sup.2 represents an alkyl group having 1 to 10 carbon atoms which may be substituted or the like; orB represents sulfonyl group; and R.sup.2 represents a lower alkenyl group or the like;R.sup.1 represents hydrogen atom or the like; R.sup.3 represents hydrogen atom or the like; R.sup.4 represents hydrogen atom or the like; and R.sup.5 represents hydrogen atom or the like,or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a pyridazinone compound represented by the formula: ##STR1## wherein (1) R.sup.1 is a substituted or unsubstituted C.sub.1-10 alkyl, a C.sub.3-6 cycloalkyl, a lower alkenyl, a heterocyclic group having N, O or S atom or camphor-10-yl; R.sup.3 is hydrogen, a substituted or unsubstituted lower alkyl or a lower alkenyl; or R.sup.1 and R.sup.3 are bonded at terminal ends thereof to form a lower alkylene; and Z is a group represented by the formula: ##STR2## where n is 1 or 2; and D is hydrogen or a halogen; or (2) R.sup.1 is a substituted or unsubstituted C.sub.1-10 alkyl, a substituted or unsubstituted phenyl, a C.sub.3-6 cycloalkyl, a lower alkenyl, a heterocyclic group having N, O or S atom or camphor-10-yl; R.sup.3 is hydrogen, a substituted or unsubstituted lower alkyl or a lower alkenyl; or R.sup.1 and R.sup.3 are bonded at terminal ends thereof to form a lower alkylene; and Z is a group represented by the formula: ##STR3## and R.sup.

Abstract: Disclosed is a pyridazinone compound represented by the formula (I): ##STR1## wherein X represents hydrogen atom or the like; Y represents a single bonding arm, oxygen atom or sulfur atom; A represents a straight or branched alkylene group which may have a double bond;B represents carbonyl group or thiocarbonyl group; and R.sup.2 represents an alkyl group having 1 to 10 carbon atoms which may be substituted or the like; orB represents sulfonyl group; and R.sup.2 represents a lower alkenyl group or the like;R.sup.1 represents hydrogen atom or the like; R.sup.3 represents hydrogen atom or the like; R.sup.4 represents hydrogen atom or the like; and R.sup.5 represents hydrogen atom or the like,or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are an indane compound represented by the formula: ##STR1## wherein R.sup.1 represents a lower alkyl group, a lower alkenyl group or a substituted or unsubstituted mono-cyclic aromatic heterocyclic group having nitrogen atom as a hetero atom; R.sup.2 represents hydrogen atom or a lower alkyl group; and A represents a lower alkylene group,or a pharmaceutically acceptable salt thereof and processes for preparing the same.

Abstract: Disclosed are an indane compound represented by the formula: ##STR1## wherein R.sup.1 is aryl, lower alkyl, cycloalkyl, halogeno-lower alkyl, lower alkenyl, phenyl-substituted lower alkenyl, monocyclic or bicyclic aromatic heterocyclic having N, O or S as a hetero atom, lower alkoxy, phenoxy, lower alkylamino, lower alkenylamino, phenyl-amino, lower alkyl substituted by monocyclic or bicyclic aromatic heterocyclic having N, O or S as a hetero atom, or lower alkenyloxy; R.sup.2 is H or lower alkyl; X is carbonyl or thiocarbonyl; Alk is single bonding arm or lower alkylene; and the dotted line is presence or absence of a double bond, or a pharmaceutically acceptable salt thereof, processes for preparing the same and a synthetic intermediate thereof.

Abstract: Disclosed are indane compounds represented by the formula: ##STR1## wherein R.sup.1 is aryl, lower alkyl, cycloalkyl, halogeno-lower alkyl, lower alkenyl, phenyl-substituted lower alkenyl, monocyclic or bicyclic aromatic heterocyclic having N, O or S as a hetero atom, lower alkoxy, phenoxy, lower alkylamino, lower alkenylamino, phenylamino, lower alkyl substituted by monocyclic or bicyclic aromatic heterocyclic having N, O or S as a hetero atom, or lower alkenyloxy; R.sup.2 is H or lower alkyl; X is carbonyl or thiocarbonyl; Alk is single bonding arm or lower alkylene; and the dotted line is presence or absence of a double bond, for treating endotoxin shock and/or nephritis.